Nynikka Palmer, DrPH, MPH
Assistant Professor
Dr. Nynikka Palmer received her undergraduate training from Morgan State University, where she obtained a degree in health education with honors. She then earned a master’s degree in public health from Emory University’s Rollins School of Public Health and subsequently worked for 3 years at the American Cancer Society in Atlanta, Georgia collaborating with community organizations on cancer education and early detection in minority and underserved communities. Dr. Palmer then earned a doctorate in public health, in behavioral sciences and health promotion from the University of Texas, School of Public Health in Houston. During her doctoral program, she was a pre-doctoral fellow in an NCI-sponsored cancer prevention and control training program. She extended her training in cancer with a focus on cancer survivorship and health disparities as a postdoctoral fellow on an NCI-sponsored training award at Wake Forest School of Medicine. Dr. Palmer was recruited to join the faculty at UCSF in 2013 to further establish her research in cancer health disparities. Currently, she is an Assistant Professor, with a primary appointment in the Division of General Internal Medicine at Zuckerberg San Francisco General Hospital and Trauma Center (ZSFGH) and secondary appointments in Urology and Radiation Oncology. Dr. Palmer is also an Associate member of the UCSF Helen Diller Family Comprehensive Cancer Center and an Associate Faculty member of the Center for Vulnerable Populations at ZSFGH.
Dr. Palmer’s research is grounded in cancer disparities and has progressed over the years to focus on racial/ethnic and geographic disparities (e.g., rural/urban) in cancer, challenges faced by male cancer survivors, prostate cancer in African American men, and quality cancer care. During her postdoctoral fellowship, she examined racial/ethnic disparities in health care receipt among male cancer survivors, rural/urban disparities in cancer survivors forgoing care because of cost, and racial/ethnic disparities in patient-provider communication, quality of care ratings, and patient activation among long-term cancer survivors. Dr. Palmer is particularly interested in prostate cancer among African American men, and has examined African American prostate cancer survivors’ treatment decision-making and their subsequent quality of life. Findings from these studies have directed her research agenda to further understand and examine quality of care and patient-provider communication among African American men with prostate cancer, particularly in low-income communities. Dr. Palmer’s long-term goal is to move beyond identifying cancer disparities to developing, implementing, and disseminating interventions and programs that will ultimately reduce the burden of cancer among vulnerable populations.
Dr. Palmer’s research is grounded in cancer disparities and has progressed over the years to focus on racial/ethnic and geographic disparities (e.g., rural/urban) in cancer, challenges faced by male cancer survivors, prostate cancer in African American men, and quality cancer care. During her postdoctoral fellowship, she examined racial/ethnic disparities in health care receipt among male cancer survivors, rural/urban disparities in cancer survivors forgoing care because of cost, and racial/ethnic disparities in patient-provider communication, quality of care ratings, and patient activation among long-term cancer survivors. Dr. Palmer is particularly interested in prostate cancer among African American men, and has examined African American prostate cancer survivors’ treatment decision-making and their subsequent quality of life. Findings from these studies have directed her research agenda to further understand and examine quality of care and patient-provider communication among African American men with prostate cancer, particularly in low-income communities. Dr. Palmer’s long-term goal is to move beyond identifying cancer disparities to developing, implementing, and disseminating interventions and programs that will ultimately reduce the burden of cancer among vulnerable populations.